

**Supplementary table S1. ICD10-codes and ATC-codes used to define cases, comorbidities and outcomes.**

<b>Diagnosis</b>	<b>ICD10-codes</b>
Ankylosing spondylitis	M45
Undifferentiated spondyloarthritis	M46.8, M46.9, M46.0, M46.1
Anterior uveitis	H20, H221
Inflammatory bowel disease	K50, K51
Psoriasis	L40
<b>Treatment</b>	<b>ATC-codes</b>
Psoriasis treatment	D05, excluding D05AA

**Supplementary table S2. Univariable HR for on-treatment anterior uveitis.**

*Legend: For dichotomous variables, the reference is zero. CRP= C-reactive protein, ESR= erythrocyte sedimentation rate, IBD= inflammatory bowel disease, csDMARD= conventional synthetic disease modifying anti-rheumatic drugs. BASDAI= Bath Ankylosing Spondylitis Disease Activity Index, ASDAS= Ankylosing Spondylitis Disease Activity Score.*

Variables	Hazard Ratio	p-value
Sex (0= women/1=men)	1.15	0.220
Age, continuous	1.01	0.054
CRP, continuous	1.01	0.114
ESR, continuous	1.00	0.289
IBD ever (0 = no /1 =yes)	0.83	0.467
Psoriasis ever (0 = no /1 =yes)	1.18	0.437
csDMARD at baseline (0 = no /1 =yes)	1.07	0.623
BASDAI, continuous	0.86	<0.0001
ASDAS, continuous	0.81	0.011
Patient global assessment, continuous	0.99	<0.0001
History of AU in:		
never	reference	
<1year	64	<0.0001
1-2 years	20	<0.0001
2-3 years	17	<0.0001
3-4 years	15	<0.0001
4-5 years	6	0.0023
5-10 years	8	<0.0001

**Supplementary table S3. Number of patients, events and follow-up time for analysis of anterior uveitis rates.**

*Legend: Flare definition 1: all registered visits with an AU-diagnosis separated by a gap of at least 90 days without any AU diagnosis; Flare definition 2: all registered visits with an AU diagnosis occurring at least 60 days after a previous registration (irrespective of any visits in-between). AU= anterior uveitis*

All treatment lines	N patients	N with any AU diagnosis	N of AU diagnoses	N AU flare definition 1	N AU flare definition 2	Follow-up years
Adalimumab	1006	25	54	27	29	1336
Secukinumab	456	13	31	13	14	459
Etanercept	1800	52	168	63	74	2239
Infliximab	783	13	29	14	14	1013
Golimumab	500	22	64	28	31	944
Certolizumab	306	6	16	7	7	356

**Supplementary table S4. Number of patients, events and follow-up time for analysis of rate ratios of anterior uveitis after switching adalimumab to other treatment.**

*Legend: Flare definition 1: all registered visits with an AU-diagnosis separated by a gap of at least 90 days without any AU diagnosis; Flare definition 2: all registered visits with an AU diagnosis occurring at least 60 days after a previous registration (irrespective of any visits in-between). AU= anterior uveitis*

Drug-pairs	N patients	N with any AU diagnosis	N of AU diagnoses	N AU flare definition 1	N AU flare definition 2	Follow-up years
Adalimumab	74	11	56	16	25	173
Secukinumab	74	10	62	16	31	70
Adalimumab	200	20	174	46	76	290
Infliximab	200	20	176	44	65	472
Adalimumab	516	35	175	63	86	919
Etanercept	516	61	514	133	206	1232
Adalimumab	217	33	323	84	128	541
Golimumab	217	40	299	88	132	493
Adalimumab	112	11	72	20	28	235
Certolizumab	112	11	148	25	49	144

**Supplementary table S5. Standardized differences among matched pairs in propensity score matched analyses, for variables described in table 4.**

	SEC vs ETN	ADA vs ETN	IFX vs ETN	GOL vs ETN	CER vs ETN
Line	0.008	0.013	0.012	0.068	0.026
Age	0.049	0.027	0.037	0.049	0.063
Sex	0.056	0.002	0.022	0.039	0.008
AU ever	0.050	0.017	0.041	0.043	0.039
AU 1 year	0.015	0.021	0.005	0.048	0.000
Patient Global	0.235	0.138	0.012	0.121	0.023
BASDAI	0.321	0.107	0.047	0.125	0.044